2011
DOI: 10.1590/s0004-27492011000100013
|View full text |Cite
|
Sign up to set email alerts
|

Ichthyosis follicularis, alopecia and photophobia syndrome (IFAP): report of the first case with ocular and cutaneous manifestations in Brazil with a favorable response to treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
10
1
1

Year Published

2013
2013
2020
2020

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 9 publications
(19 reference statements)
1
10
1
1
Order By: Relevance
“…Corneal scarring and erosions with corneal vascularization can also be seen in ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome . Acitretin therapy may result in a modest improvement in corneal erosions.…”
Section: Ocular Abnormalities Associated With Ichthyosismentioning
confidence: 99%
“…Corneal scarring and erosions with corneal vascularization can also be seen in ichthyosis follicularis, alopecia, and photophobia (IFAP) syndrome . Acitretin therapy may result in a modest improvement in corneal erosions.…”
Section: Ocular Abnormalities Associated With Ichthyosismentioning
confidence: 99%
“…İFAF sendromlu erkeklerde ilerleyici korneal vaskülarizasyon nedeniyle görme kaybı gelişir. İFAF sendromunda bildirilen diğer göz bulguları punktat keratopati, atopik keratokonjonktival inflamasyon, katarakt, horizantal nistagmus, astigmatizm ve miyopidir [8][9][10] . Retinal damarlarda kıvrımlı görünüm ise kadın taşıyıcılarda bildirilmiştir 8 .…”
Section: Discussionunclassified
“…Currently, there is still no effective drug treatment for severe IFAP syndrome (IFAP/BRESHECK and IFAP/OS), whereas the symptoms of IFAP/KFSD are relatively milder and its long‐time prognosis is favourable. A positive response to systemic acitretin therapy with improvement in cutaneous features and corneal erosions has been noted in some patients; however, the long‐term disease outcome and the possible drug side effects are not clear. Regretfully, our patient refused the systemic acetritin therapy offered, and was lost to follow‐up soon afterwards.…”
Section: Reportmentioning
confidence: 99%